Connected real-life research, a pillar of P4 medicine

Nicolas Roche; Antonio Anzueto; Sinthia Bosnic Anticevich; Alan Kaplan; Marc Miravitlles; Dermot Ryan; Joan B. Soriano; Omar Usmani; Nikos Papadopoulos; G. Walter Canonica

doi:10.1183/13993003.02287-2019

Connected real-life research, a pillar of P4 medicine

Nicolas Roche, Antonio Anzueto, Sinthia Bosnic Anticevich, Alan Kaplan, Marc Miravitlles, Dermot Ryan, Joan B. Soriano, Omar Usmani, Nikos Papadopoulos, G. Walter Canonica

Division of Pulmonary Diseases

Producción científica: Letter › revisión exhaustiva

5 Citas (Scopus)

Idioma original	English (US)
Número de artículo	1901866
Publicación	European Respiratory Journal
Volumen	55
N.º	1
DOI	https://doi.org/10.1183/13993003.02287-2019
Estado	Published - ene 1 2020

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Acceder al documento

10.1183/13993003.02287-2019

Otros archivos y enlaces

Citar esto

@article{0125a4c40fa941db88093e3e83d3ddd9,

title = "Connected real-life research, a pillar of P4 medicine",

author = "Nicolas Roche and Antonio Anzueto and Anticevich, \{Sinthia Bosnic\} and Alan Kaplan and Marc Miravitlles and Dermot Ryan and Soriano, \{Joan B.\} and Omar Usmani and Nikos Papadopoulos and \{Walter Canonica\}, G.",

note = "Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M, Zambon and Trudell, outside the submitted work. A. Anzueto reports personal fees for consultancy from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, outside the submitted work. S. Bosnic Anticevich reports personal fees for advisory board work from TEVA, personal fees for consultancy from GSK and MEDA, grants from TEVA, personal fees for lectures from TEVA, GSK and AstraZeneca, personal fees for manuscript preparation from MEDA, personal fees for educational activities from GSK, outside the submitted work. A. Kaplan reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Pfizer, personal fees from Covis, GSK, Sanofi, Merck Frosst, Novartis, Purdue, Teva, Trudel, Novo Nordisk and Griffols, during the conduct of the study. M. Miravitlles reports personal fees for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis, personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols, grants from GlaxoSmithKline and Grifols, outside the submitted work. D. Ryan reports personal fees for advisory board work from GSK, BI, AZ and Novartis, personal fees for lectures from AZ and MEDA, grants meeting registration from MEDA, outside the submitted work; and is Previous President and Current Vice President of REG, and Consultant Strategic Medical Adviser, Optimum Patient Care. J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda; J.B. Soriano declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates. O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva and Cipla, grants from GlaxoSmithKline and Edmond Pharma, outside the submitted work. N. Papadopoulos reports personal fees for advisory board work and lectures from Novartis, Nutricia, HAL, MENARINI/FAES FARMA and MYLAN/MEDA, personal fees for lectures from SANOFI, BIOMAY, MSD, ASIT BIOTECH and Boehringer Ingelheim, personal fees for advisory board work from AstraZeneca and GSK, grants from Gerolymatos International SA and Capricare, outside the submitted work. G.W. Canonica has nothing to disclose.",

year = "2020",

month = jan,

day = "1",

doi = "10.1183/13993003.02287-2019",

language = "English (US)",

volume = "55",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "1",

}

TY - JOUR

T1 - Connected real-life research, a pillar of P4 medicine

AU - Roche, Nicolas

AU - Anzueto, Antonio

AU - Anticevich, Sinthia Bosnic

AU - Kaplan, Alan

AU - Miravitlles, Marc

AU - Ryan, Dermot

AU - Soriano, Joan B.

AU - Usmani, Omar

AU - Papadopoulos, Nikos

AU - Walter Canonica, G.

N1 - Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M, Zambon and Trudell, outside the submitted work. A. Anzueto reports personal fees for consultancy from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, outside the submitted work. S. Bosnic Anticevich reports personal fees for advisory board work from TEVA, personal fees for consultancy from GSK and MEDA, grants from TEVA, personal fees for lectures from TEVA, GSK and AstraZeneca, personal fees for manuscript preparation from MEDA, personal fees for educational activities from GSK, outside the submitted work. A. Kaplan reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Pfizer, personal fees from Covis, GSK, Sanofi, Merck Frosst, Novartis, Purdue, Teva, Trudel, Novo Nordisk and Griffols, during the conduct of the study. M. Miravitlles reports personal fees for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis, personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols, grants from GlaxoSmithKline and Grifols, outside the submitted work. D. Ryan reports personal fees for advisory board work from GSK, BI, AZ and Novartis, personal fees for lectures from AZ and MEDA, grants meeting registration from MEDA, outside the submitted work; and is Previous President and Current Vice President of REG, and Consultant Strategic Medical Adviser, Optimum Patient Care. J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda; J.B. Soriano declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates. O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva and Cipla, grants from GlaxoSmithKline and Edmond Pharma, outside the submitted work. N. Papadopoulos reports personal fees for advisory board work and lectures from Novartis, Nutricia, HAL, MENARINI/FAES FARMA and MYLAN/MEDA, personal fees for lectures from SANOFI, BIOMAY, MSD, ASIT BIOTECH and Boehringer Ingelheim, personal fees for advisory board work from AstraZeneca and GSK, grants from Gerolymatos International SA and Capricare, outside the submitted work. G.W. Canonica has nothing to disclose.

PY - 2020/1/1

Y1 - 2020/1/1

UR - https://www.scopus.com/pages/publications/85077940941

UR - https://www.scopus.com/inward/citedby.url?scp=85077940941&partnerID=8YFLogxK

U2 - 10.1183/13993003.02287-2019

DO - 10.1183/13993003.02287-2019

M3 - Letter

C2 - 31949104

AN - SCOPUS:85077940941

SN - 0903-1936

VL - 55

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 1

M1 - 1901866

ER -